JPMorgan Chase & Co. (JPM) Analysts Reiterate a "Neutral" Rating on Biogen ... LocalizedUSA It includes BG-12, Daclizumab, Fampridine, GA101, Humanized Anti-CD20 MAb (ocrelizumab), Lixiavaptan, Long-Acting rFactor IX and PEGylated interferon beta-1a. Shares of Biogen Idec traded up 5.96% during mid-day trading on Friday, hitting $107.73. ... |
